Creative Biolabs is a leader in biotechnology, providing Custom IVT Synthesis of mRNA tailored for diverse research and clinical applications. Our team, with over ten years of experience in mRNA synthesis and modifications, delivers IVT services characterized by exceptional purity and biological activity. IVT mRNA, crucial in regenerative medicine, vaccinations, and cell engineering, offers a safe, effective gene therapy vector. We are dedicated to propelling gene therapy innovations and support all scientific endeavors with our expert, reliable solutions.
Fig.1 Preparation of synthetic mRNA by IVT.
By sending us the DNA plasmid or the gene sequence, Creative Biolabs can synthesize a high-quality mRNA depending on the customers' experimental purposes. IVT RNA synthesis requires DNA templates, enzymes, nucleotides, and buffer components. With the experience of the IVT system, Creative Biolabs can offer optimization of each reaction component and several internal epigenetic modifications to obtain high-yield synthesized IVT mRNA for our customers, including but not limited to:
Aiming for protein expression or translation process through synthesized mRNA, all these options are important for improved stability and translation efficiency. Moreover, we can also offer the modifications of mRNA after synthesis to achieve the specific requirements of our customers. To obtain a pristine IVT mRNA, we also offer the large-scale purification step (using PAGE or RP-HPLC methods) to remove the residual molecules, such as unreacted nucleotides, short oligonucleotides, enzyme proteins, and residual salts. These methods remove most of the unwanted byproducts and provide high-quality IVT mRNAs. Our IVT synthesis strategy is very suitable for particularly long mRNAs (such as those up to multiple kilobases), and our experts can design custom strategies to optimize the yield even for the most complicated custom mRNA production requirements.
In addition, we can also provide self-amplifying RNA (saRNA), which is an advanced form of RNA technology designed to enhance the expression of encoded proteins. Unlike conventional mRNA, saRNA includes additional sequences that allow it to replicate itself within the host cell, thereby amplifying the production of the target protein. This technology has significant implications for vaccine development, gene therapy, and protein production.
Inquire About Our ServicesA: The turnaround time varies depending on the complexity and scale, but Creative Biolabs aims for a fast and efficient process, typically within a few weeks.
A: Applications include therapeutic development, vaccine production, functional genomics, and cell reprogramming.
A: We employ rigorous quality control measures including purity checks, integrity analysis, and functionality assays.
A: They use various promoters like T7, SP6, and T3, depending on the specific requirements of the project.
A: Yes, we offer incorporation of modified nucleotides to enhance mRNA stability and reduce immunogenicity.
A: Customization includes various DNA template designs, promoter systems, codon optimization, 5'- and 3'-UTR optimization, and poly(A) tail length adjustments.
This article focuses on improving the synthesis of high-integrity mRNA via in vitro transcription (IVT). The main challenge addressed is the generation of fragmented mRNA during the synthesis process, which impedes the efficacy of mRNA therapeutics. The study identifies specific domains in T7 RNA polymerase responsible for premature termination and mRNA fragmentation. By engineering T7 RNA polymerase mutants and optimizing IVT parameters, the researchers achieved mRNA integrity exceeding 91%. The research emphasizes the importance of full-length mRNA transcripts for effective in vivo expression and highlights strategies to reduce impurities, thereby enhancing the potential of mRNA-based therapies.
Fig.2 Analysis of mRNA products by capillary electrophoresis method.1
| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
